---
title: "Tumor Microenvironment"
---
# Tumor Microenvironment
`technology · cancer biology · immunotherapy · TME · spatial biology · immune infiltration · biomarker · ecotype`

Last modified 2026-06-04 · 7 papers · 15 outgoing links · 4 incoming links

| | |
|---|---|
| **Type** | Cellular ecosystem |
| **Key determinant** | Immunotherapy response |
| **Critical effector** | [[cd8-t-cells\|CD8+ T cells]] |
| **Suppressive cells** | TAMs, [[regulatory-t-cells\|Tregs]] |
| **Resistance axes** | CD73/adenosine, IL-17, [[spp1\|SPP1]] |
| **Cancers** | NSCLC, melanoma, gastric, pancreatic |
| **Papers** | 7 indexed |
| **Incoming links** | 4 wiki entities |

---

**The tumor microenvironment (TME)** is a complex, heterogeneous cellular compartment comprising cancer cells, immune cells, stromal elements, and metabolic regulators that critically determines [[immune-checkpoint-inhibitor|immune checkpoint inhibitor (ICI)]] efficacy and clinical outcomes across multiple cancer types. Rather than a uniform terrain, the TME exists along a spectrum from "hot" (immune-infiltrated, immunotherapy-responsive) to "cold" (reduced immune infiltration, [[spp1|SPP1]]-high, immunotherapy-resistant) phenotypes that link genomic subtypes to treatment outcomes.¹ ² Among diverse intratumoral lymphocyte populations including Th1 cells, [[regulatory-t-cells|regulatory T cells]], and [[nk-cells|NK cells]], only [[cd8-t-cells|CD8+ tumor-infiltrating lymphocytes (TILs)]] consistently associate with ICI efficacy in metastatic [[nsclc|non-small cell lung cancer (NSCLC)]], with their presence, functional state (CD39+/CD103+/Ki-67+), and direct physical proximity to cancer cells predicting treatment response.¹

---

## Architecture and cellular organization

The TME comprises spatially organized cellular neighborhoods whose structural relationships encode therapeutic information. Computational tissue segmentation reveals that direct physical interactions between [[cd8-t-cells|CD8+ TILs]] and cancer cells are essential for ICI efficacy, underscoring that cell-cell spatial relationships provide superior predictive power compared to single biomarkers such as [[pd-l1|PD-L1]] expression or tumor mutational burden.¹ ³ Multi-omics integration across genomics, epigenomics, transcriptomics, proteomics, post-translational modifications, and metabolomics defines distinct tumor ecotypes with characteristic TME architectures and molecular programs that link microenvironmental features to clinical outcomes and immunotherapy response in gastric cancer and other malignancies.⁷ These ecotype-specific signatures refine genomic and histological subtypes by capturing tumor microenvironment organization patterns that determine therapeutic vulnerability.

---

## Immunotherapy prediction and response

ZNF683+ [[cd8-t-cells|CD8+ T cells]] emerge as a crucial subset enriched in immunotherapy responders, with ZNF683 expression serving as a robust indicator of TME immune activation and treatment responsiveness in NSCLC.² Computational screening of 296 algorithm combinations established the [[znfrs|ZNF683+ CD8+ T cell-related Riskscore (ZNFRS)]] using the optimal StepCox[forward] + Ridge combination, demonstrating superior prognostic capability for lung adenocarcinoma patients.² A novel tumor inflammation score integrating [[regulatory-t-cells|regulatory T cell]]/CD3+ T cell spatial proximity with overall T-cell density correlates strongly with disease response (p < 0.002), indicative of an ongoing anticancer immune response.³ Phenotyping of CD8+ TILs identifies CD39/CD103/Ki-67 positivity as a hallmark of exhausted yet functional tumor-reactive effector cells, distinguishing productive anti-tumor immunity from mere lymphocyte presence.¹

---

## Resistance mechanisms

Immunosuppressive cellular and molecular components actively mediate immune evasion within the TME. Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts represent independent unfavorable adversaries that limit ICI efficacy.¹ High CD73 expression on cancer cells confers tolerance to ICI in [[egfr|EGFR]]/[[alk|ALK]]-oncogene+ NSCLC, potentially through M2-TAM accumulation and aberrant angiogenesis, establishing the CD73/adenosine axis as a critical metabolic regulator of immune suppression.¹ High-[[znfrs|ZNFRS]] tumors exhibit a "cold" TME phenotype characterized by reduced immune infiltration, immunotherapy resistance, and enhanced [[spp1|SPP1]] signaling; in vivo experiments demonstrate that anti-SPP1 treatment suppresses tumor growth, restores [[cd8-t-cells|CD8+ T cell]] effector function, inhibits M2-like macrophage polarization, and significantly enhances [[anti-pd-1-therapy|anti-PD-1]] efficacy.² IL-17-driven HIF-1α/VEGF-A signaling further mediates immune evasion in [[melanoma]] brain metastases, where metabolic regulators within the TME limit the efficacy of CD73-directed antibodies.⁴

---

## Therapeutic remodeling strategies

Engineering immune cells within the TME using lipid nanoparticle-delivered immune-remodeling mRNAs (IR-mRNAs) encoding [[irf8|interferon regulatory factor 8 (IRF8)]] or [[nik|NF-κB-inducing kinase (NIK)]] activates antigen-presenting cells, significantly increasing activated type 1 conventional dendritic cells, immunostimulatory cytokines, and priming antitumor [[cd8-t-cells|CD8+ T cell]] responses with durable antitumor immunity across multiple syngeneic mouse tumor models.⁵ Coadministration of IR-mRNA with antigen-encoding mRNA elicits 10-fold increases in antigen-specific CD8+ T cell responses and sustained long-term memory.⁵ For melanoma brain metastases, a nose-to-brain delivery platform using glycerol as a mucosal penetration enhancer codelivers anti-IL-17 and anti-CD73 antibodies, where anti-IL-17 attenuates CD73/adenosine axis-mediated immune evasion, promoting CD8+ T cell activation and residency, pro-inflammatory macrophage polarization, and reduced [[regulatory-t-cells|Treg]] infiltration.⁴ Multimodal approaches integrate photothermal therapy, chemodynamic therapy via Cu⁺-mediated cuproptosis, and hydrogen sulfide gas therapy to reverse TME immunosuppression by promoting macrophage repolarization and vascular normalization.⁶

---

## Beyond NSCLC

While extensively characterized in lung cancer, TME profiling extends therapeutic insights across malignancies. In gastric adenocarcinoma, a 15-layer multi-omics atlas integrating genomics through microbiome profiles defines tumor ecotypes that refine genomic and histological subtypes by capturing distinct TME architectures linked to clinical outcomes and potential associations with immunotherapy response.⁷ Cell-state deconvolution prioritizes ecotype-specific transcriptional programs, signaling pathways, post-translational modifications, protein interaction networks, and metabolic regulation, identifying microbiome features linked to ecotypes and resistance pathways.⁷ This systems-level characterization provides a blueprint for decoding TME heterogeneity and advancing precision oncology by prioritizing ecotype-, genomic subtype-, and cell type-specific targetable proteins within a tumor microenvironment context.

---

## References
1. PMID:41805727 — Spatial single-cell proteotyping reveals immunotherapy-resistant features in mNSCLC TME
2. PMID:42115771 — ZNF683+ CD8+ T cells predict immunotherapy response; SPP1 targeting enhances anti-PD-1
3. PMID:42126144 — Tumor inflammation score based on Treg/T cell spatial relationships predicts pembrolizumab response
4. PMID:42127192 — Nose-to-brain anti-IL-17/anti-CD73 codelivery for melanoma brain metastases
5. PMID:42129506 — IRF8 and NIK immune-remodeling mRNAs generate durable antitumor immunity
6. PMID:41605106 — Cascade-responsive H₂S-releasing nanoplatform for photothermal-immunotherapy
7. PMID:42013851 — 15-layer multi-omics atlas defines gastric cancer ecotypes and TME architectures